Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C59H84N16O12 |
| Molecular Weight | 1209.3983 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6)C(C)(C)C
InChI
InChIKey=XJWIEWPGHRSZJM-MGZASHDBSA-N
InChI=1S/C59H84N16O12/c1-7-63-55(85)46-15-11-23-75(46)57(87)40(14-10-22-64-58(60)61)68-50(80)41(24-32(2)3)72-56(86)48(59(4,5)6)74-53(83)42(25-33-16-18-36(77)19-17-33)69-54(84)45(30-76)73-51(81)43(26-34-28-65-38-13-9-8-12-37(34)38)70-52(82)44(27-35-29-62-31-66-35)71-49(79)39-20-21-47(78)67-39/h8-9,12-13,16-19,28-29,31-32,39-46,48,65,76-77H,7,10-11,14-15,20-27,30H2,1-6H3,(H,62,66)(H,63,85)(H,67,78)(H,68,80)(H,69,84)(H,70,82)(H,71,79)(H,72,86)(H,73,81)(H,74,83)(H4,60,61,64)/t39-,40-,41-,42-,43-,44-,45-,46-,48-/m0/s1
| Molecular Formula | C59H84N16O12 |
| Molecular Weight | 1209.3983 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:30:24 UTC 2023
by
admin
on
Sat Dec 16 17:30:24 UTC 2023
|
| Record UNII |
ZD8NZ8J5LN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
61012-19-9
Created by
admin on Sat Dec 16 17:30:25 UTC 2023 , Edited by admin on Sat Dec 16 17:30:25 UTC 2023
|
PRIMARY | |||
|
Lecirelin
Created by
admin on Sat Dec 16 17:30:25 UTC 2023 , Edited by admin on Sat Dec 16 17:30:25 UTC 2023
|
PRIMARY | |||
|
DTXSID00735365
Created by
admin on Sat Dec 16 17:30:25 UTC 2023 , Edited by admin on Sat Dec 16 17:30:25 UTC 2023
|
PRIMARY | |||
|
66577115
Created by
admin on Sat Dec 16 17:30:25 UTC 2023 , Edited by admin on Sat Dec 16 17:30:25 UTC 2023
|
PRIMARY | |||
|
ZD8NZ8J5LN
Created by
admin on Sat Dec 16 17:30:25 UTC 2023 , Edited by admin on Sat Dec 16 17:30:25 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Agonists do not quickly dissociate from the GnRH receptor. As a result, initially there is an increase in FSH and LH secretion (so-called "flare effect"). Levels of LH may increase by up to 10-fold,[15][16] while levels of testosterone generally increase to 140 to 200% of baseline values. However, after continuous administration, a profound hypogonadal effect (i.e. decrease in FSH and LH) is achieved through receptor downregulation by internalization of receptors. Generally this induced and reversible hypogonadism is the therapeutic goal.
|
||
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
